Results for this period
Third quarter1 June 2025–28 February 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The main factors were a substantial improvement in inventory write-downs and a decrease in selling, general and administrative expenses, primarily due to a decrease in research and development expenses. Active pharmaceutical ingredients saw an increase in anti-allergy drug ingredients but a decrease in hemostatic and anticoagulant drug ingredients. Formulated products remained firm, including generic and over-the-counter pharmaceuticals, while products for generic pharmaceuticals also increased.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 June 2025–28 February 2026 |
| Net Sales | 36,732 million yen (YoY +0.3%) |
| Operating profit | 2,751 million yen (YoY +47.2%) |
| Ordinary income | 2,974 million yen (YoY +46.2%) |
| Profit attributable to owners of the parent | 2,267 million yen (YoY +86.2%) |
| Net income per share | ¥76.53 |
| Equity ratio | End of the current fiscal period 69.7% / End of previous period 66.7% |
| Total assets | 74,963 million yen |
| Net assets | 52,336 million yen |
| Full-year earnings forecast | Net Sales 51,000 million yen (YoY +0.7%) / Operating profit 3,300 million yen (YoY +26.0%) / Ordinary income 3,500 million yen (YoY +29.4%) / Net income 2,500 million yen (YoY +31.0%) |
| Revision to Earnings Forecast | Not disclosed → Net Sales 51,000 million yen / Operating profit 3,300 million yen / Ordinary income 3,500 million yen / Net income 2,500 million yen |
| Annual Dividend Forecast | 70 yen → 40 yen（-42.9%） |
| Depreciation and amortization | 3,273 million yen |
| Breakdown of extraordinary income (loss) | Gain on sale of investment securities 331 million yen, Loss on Disposal of Fixed Assets 35 million yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes Yes / Change in accounting estimate Yes / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 1 / Company name 大和薬品工業株式会社 |
| Material subsequent events | From 1 March to 31 March 2026, 208,800 shares of treasury stock were acquired for ¥305 million. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 30,096,880 Shares |
| Treasury Shares at Period-End | 933,038 Shares |
| Factors Behind Changes in Business Performance | The main factors were a substantial improvement in inventory write-downs and a decrease in selling, general and administrative expenses, primarily due to a decrease in research and development expenses. Active pharmaceutical ingredients saw an increase in anti-allergy drug ingredients but a decrease in hemostatic and anticoagulant drug ingredients. Formulated products remained firm, including generic and over-the-counter pharmaceuticals, while products for generic pharmaceuticals also increased. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Selling, general and administrative expenses decreased, primarily due to a decrease in research and development expenses, in addition to a substantial improvement in inventory write-downs. In addition, operating income and other items increased by ¥158 million due to a change in the depreciation method.